Available online at www.sciencedirect.com
SCIENCE DIRECT®
Bioorganic & Medicinal Chemistry Letters 15 (2005) 149–151
Bioorganic & Medicinal Chemistry Letters

5′-Homoaristeromycin. Synthesis and antiviral activity against orthopox viruses

Minmin Yang and Stewart W. Schneller*

Department of Chemistry and Biochemistry, Auburn University, Auburn, AL 36849, USA

Received 9 September 2004; revised 6 October 2004; accepted 6 October 2004
Available online 28 October 2004

Abstract—An efficient synthesis of 5′-homoaristeromycin has been developed. This permitted an extensive antiviral analysis, which found potent activity toward vaccinia, cowpox, and monkeypox viruses. For comparative purposes, 5′-homoadenosine was made available by a newly designed route and found to be inactive.

Inhibitors of *S*-adenosyl-L-homocysteine (AdoHcy) hydrolase have shown promise as antiviral agents[1,2] by disrupting essential viral macromolecular methylation processes.[2] Carbocyclic nucleosides [3] represent a prominent class of compounds whose antiviral potential has been traced to such an effect.[1] Within that group, carbocyclic adenosine (aristeromycin, **1**) is at the center of these investigations[4] but its promise is limited by a toxicity arising from 5′-phosphate formation.[5]

Structural modifications of **1** with the aim of reducing phosphate-based toxicity have yielded meaningful drug candidates.[6] An approach not explored, however, is extension of the C-5′ hydroxymethyl side chain by a methylene group to provide the C-5′ homolog of aristeromycin (**2**). This analog can be expected[7] to have displaced the phosphate-susceptible hydroxyl from the phosphate-transfer zone in the kinases responsible for metabolism to **1** to its nucleotides. In support of this, **2** has been reported[8] to be inactive against HSV-1 and HSV-2, possibly, due to its failure to be phosphorylated (Fig. 1).

To investigate **2** more thoroughly as a possible antiviral agent a more practical synthesis of it was necessary. For comparative antiviral purposes, 5′-homoadenosine (**3**) was also sought by a much more efficient way than exists in the literature.[9] The results of this effort are communicated here.



1, X = CH_2, n = 1
2, X = CH_2, n = 2
3, X=O, n=2

Figure 1.

Existing methods[8,10,11] for preparing 5′-homoaristeromycin (**2**) suffer from too many steps, limited scale-up, low yields and, in one case, resulting in a racemic product. Therefore, an efficient and stereoselective synthesis of **2** was needed. Starting from enone **4**[12] (Scheme 1), 1,4-addition of ethyl trimethylsilylacetate followed by in situ cleavage of the trimethylsilyl group furnished, stereoselectively, the ketone ester **5** as the only product. The stereochemistry at C-4 of **5** was derived from the fact (i) that a 1,4-addition to the concave structure of **5** can be expected[13] to give a β (up) product and (ii) that **5** was converted into the known **2**. Reduction of **5** with sodium borohydride provided the coupling precursor **6**, which has been reported via a more tedious way.[14] Mitsunubo coupling reaction of **6** with 6-chloropurine furnished **7**. Selective reduction of **7** with diisobutylaluminum hydride (DIBAL) yielded the desired alcohol **8**.

Keywords: Carbocyclic nucleosides; Nucleoside homologation; Monkeypox.
* Corresponding author. Tel.: +1 334 844 5737; fax: +1 334 844 5748; e-mail: schnest@auburn.edu

0960-894X/$ - see front matter © 2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmcl.2004.10.019



Scheme 1. Reagents and conditions: (a) (i) ethyl (trimethylsilyl)acetate, *n*-BuLi, DIPA, HMPA/THF, −78 °C, (ii) KF, EtOH/H_2O, rt, 84% for two steps from **4**; (b) $NaBH_4$, MeOH, ice temp, 100%; (c) 6-chloropurine, Ph_3P, DIAD, THF, 0–50 °C, 52%; (d) DIBAL, CH_2Cl_2, −50 °C, 80%; (e) NH_3/MeOH, 94%; (f) HCl/MeOH, 95%.



Scheme 2. Reagents and conditions: (a) (i) DMSO, DIPEA, SO_3-Py, CH_2Cl_2, 90%, (ii) Ph_3PCH_3Br, *t*-BuOK, Et_2O, 75%; (b) 9-BBN, THF, then NaOH, H_2O_2, 97%; (c) (i) 70% AcOH, 85 °C; (ii) Ac_2O, DMAP, pyridine, 85% for two steps from **12**; (d) Adpiv, HMDS, TMSCl, TMSOTf, 60%; (e) NH_3/MeOH, 91%.

Ammonolysis of **8** (to **9**) followed by hydrolytic deprotection smoothly afforded **2** in good overall yield.[15]

The known syntheses of 6′-homoadenosine[9] (**3**) either involved many steps[9a] or suffer a low yield of the final product.[9b,c] Our plan (Scheme 2) envisioned beginning with homologation of **10**.[16] Side chain oxidation of **10** followed by Wittig olefination afforded **11**. Submitting **11** to regioselective hydroboration with 9-BBN followed by oxidative hydrolysis, smoothly provided **12** in high yield. Hydrolysis of **12** with acetic acid produced a tetrol, which was fully protected with acetic anhydride to provide the anomeric acetate **13**. The coupling reaction of **13** with *N*-pivaloyl protected adenine under Vorbrüggen glycosylation conditions yielded the desired N-9 product **14** as the only isolated product. Deprotection of **14** with ammonia furnished **3** in good overall yield[17] from D-ribose.

Compounds **2** and **3** were evaluated against a wide variety of both DNA viruses and RNA viruses.[18] From this, very significant effects were seen for **2** toward vaccinia (IC_{50} 1.2 μg/mL), cowpox (IC_{50} 0.12 μg/mL), and monkeypox (IC_{50} 0.12 μg/mL) viruses, all in Vero 76 cells with $CC_{50} > 100$ μg/mL. This observation is particularly noteworthy since it is well known that vaccinia is susceptible to AdoHcy hydrolase inhibitors but cowpox was thought not to be.[18e] In any case, details of this investigation and the, possibly, less notable activity of **2** toward other viruses[18] will be forthcoming, including its potency toward variola.[19] Analog **3** was inactive in all of the assays employed.[18]

Acknowledgements

This research was supported by funds from the NIH (AI 56540). We are also indebted to the following individu-

als for providing the antiviral data: Dr. Erik De Clercq, the Rega Institute, Leuven Belgium; Dr. Earl Kern, University of Alabama at Birmingham, Birmingham, AL; Dr. Brent Korba, Georgetown University, Washington, DC; Dr. Robert Sidwell, Utah State University, Logan, UT; and, Dr. John Huggins, U.S. Army Medical Research Institute of Infectious Diseases Frederick, MD.

References and notes

1. De Clercq, E. *Nat. Rev. Drug Discovery* **2002**, *1*, 13.
2. Liu, S.; Wolfe, M. S.; Borchardt, R. T. *Antiviral Res.* **1992**, *19*, 247.
3. Rodriguez, J. B.; Comin, M. J. *Mini-Rev. Med. Chem.* **2003**, *3*, 95.
4. Yuan, C.-S.; Liu, S.; Wnuk, S. F.; Robins, M. J.; Borchardt, R. T. *Adv. Antiviral Drug Des.* **1996**, *2*, 41.
5. (a) Bennett, L. L., Jr.; Allan, P. W.; Rose, L. M.; Comber, R. N.; Secrist, J. A., III. *Mol. Pharmacol.* **1986**, *29*, 383; (b) Bennett, L. L.; Bowdon, B. J.; Allan, P. W.; Rose, L. M. *Biochem. Pharmacol.* **1986**, *35*, 4106.
6. (a) Hasobe, M.; Liang, H.; Ault-Riche, D. B.; Borcherding, D. R.; Wolfe, M. S.; Borchardt, R. T. *Antiviral Chem. Chemother.* **1993**, *4*, 245; (b) Rajappan, V. P.; Schneller, S. W.; Williams, S. L.; Kern, E. R. *Bioorg. Med. Chem.* **2002**, *10*, 883.
7. Shuto, S.; Obara, T.; Saito, Y.; Andrei, G.; Snoeck, R.; De Clercq, E.; Matsuda, A. *J. Med. Chem.* **1996**, *39*, 2392.
8. Jones, M. F.; Roberts, S. M. *J. Chem. Soc., Perkin Trans. 1* **1988**, *11*, 2927.
9. (a) Robins, M. J.; Guo, Z. Q.; Wnuk, S. F. *J. Am. Chem. Soc.* **1997**, *119*, 3637; (b) Kappler, F.; Hampton, A. In *Nucleic Acid Chemistry: Improved and New Synthetic Procedures Methods and Techniques*; Townsend, L. B., Tipson, R. S., Eds.; Wiley: New York, 1991; p 240; (c) Mikhailov, S. N.; Padyukova, N. S.; Karpeiskii, M. Y.; Kolobushkina, L. I.; Beigelman, L. N. *Collect. Czech. Chem. Commun.* **1989**, *54*, 1055; (d) Hollmann, J.; Schlimme, E. *Liebigs Ann. Chem.* **1984**, *1*, 98.
10. Siddiqi, S. M.; Chen, X.; Schneller, S. W. *Nucleosides Nucleotides* **1993**, *12*, 267.
11. Kapeller, H.; Baumgartner, H.; Griengl, H. *Monatsh. Chem.* **1997**, *128*, 191.
12. Yang, M.; Ye, W.; Schneller, S. W. *J. Org. Chem.* **2004**, *69*, 3993.
13. Wolfe, M. S.; Anderson, B. L.; Borcherding, D. R.; Borchardt, R. T. *J. Org. Chem.* **1990**, *55*, 4712.
14. Matsugi, M.; Gotanda, K.; Ohira, C.; Suemura, M.; Sano, A.; Kita, Y. *J. Org. Chem.* **1999**, *64*, 6928.
15. Selected data for **2**: mp 178–179 °C; ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.20 (s, 1H), 8.11 (s, 1H), 7.17 (s, 2H), 4.90 (d, J = 6.27 Hz, 1H), 4.68 (d, J = 4.63 Hz, 1H), 4.57 (m, 1H), 4.43 (t, J = 5.12 Hz, 1H), 4.35 (m, 1H), 3.71 (m, 1H), 3.46 (m, 2H), 2.24 (m, 1H), 1.97 (m, 1H), 1.74 (m, 2H), 1.58 (m, 1H);[8] ^{13}C NMR (100 MHz, $CDCl_3$) δ 156.0, 152.1, 149.6, 140.2, 119.3, 74.9, 74.3, 59.9, 59.4, 40.0, 37.4, 32.5. Anal. Calcd for $C_{12}H_{17}N_5O_3$: C, 51.60; H, 6.14; N, 25.08. Found: C, 51.39; H, 6.18; N, 24.81.
16. Ugarkar, B. G.; DaRe, J. M.; Kopcho, J. J.; Browne, C. E., III; Schanzer, J. M.; Wiesner, J. B.; Erion, M. D. *J. Med. Chem.* **2000**, *43*, 2883.
17. Selected data for **3**: mp 223–224 °C (lit.[9c] 231.5–232.5 °C); ^{1}H NMR (250 MHz, DMSO-d_6) δ 8.27 (s, 1H), 8.10 (s, 1H), 7.24 (s, 2H), 5.79 (d, J = 5.3 Hz, 1H), 5.36 (d, J = 5.7 Hz, 1H), 5.11 (d, J = 5.1 Hz, 1H), 4.61 (m, 1H), 4.44 (t, J = 5.1 Hz, 1H), 4.03 (m, 1H), 3.93 (m, 1H), 3.42 (m, 2H), 1.76 (m, 2H); ^{13}C NMR (62.9 MHz, DMSO-d_6) δ 156.1, 152.6, 149.4, 139.9, 119.2, 87.4, 81.0, 73.4, 72.9, 57.5, 36.6. Anal. Calcd for $C_{11}H_{15}N_5O_4$: C, 46.97; H, 5.38; N, 24.90. Found: C, 46.85; H, 5.48; N, 24.63.
18. For leading references on the procedures used for the assays see (a) Ref. 5; (b) Siddiqi, S. M.; Chen, X.; Schneller, S. W.; Ikeda, S.; Snoeck, R.; Andrei, G.; Balzarini, J.; De Clercq, E. *J. Med. Chem.* **1994**, *37*, 551; (c) Seley, K. L.; Schneller, S. W.; Korba, B. *Nucleosides Nucleotides* **1997**, *16*, 2095; (d) http://www.usu.edu/iar/Brochure/brochure.html (September 6, 2004); and; (e) Baker, R. O.; Bray, M.; Huggins, J. W. *Antiviral Res.* **2003**, *57*, 13.
19. Bray, M.; Roy, C. J. *J. Antimicrob. Chemother.* **2004**, *54*, 1.